Systematic Evaluation of Augmentation during Treatment with Ropinirole in Restless Legs Syndrome (Willis-Ekbom Disease): Results from a Prospective, Multicenter Study over 66 Weeks
Identifieur interne : 000040 ( PascalFrancis/Checkpoint ); précédent : 000039; suivant : 000041Systematic Evaluation of Augmentation during Treatment with Ropinirole in Restless Legs Syndrome (Willis-Ekbom Disease): Results from a Prospective, Multicenter Study over 66 Weeks
Auteurs : Diego Garcia-Borreguero [Espagne] ; Birgit Högl [Autriche] ; Luigi Ferini-Strambi [Italie] ; John Winkelman [États-Unis] ; Christina Hill-Zabala [États-Unis] ; Afsaneh Asgharian [États-Unis] ; Richard Allen [États-Unis]Source :
- Movement disorders [ 0885-3185 ] ; 2012.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Prospective.
English descriptors
- KwdEn :
Abstract
The purpose of this study was to evaluate the incidence of augmentation over 66 weeks of treatment with ropinirole in patients with primary restless legs syndrome (RLS). Augmentation is the main complication of long-term dopaminergic treatment of RLS. Despite widespread use of ropinirole in RLS, no studies have prospectively and systematically assessed the incidence of augmentation with its use. The study consisted of 26 weeks of double-blind flexible-dose treatment with ropinirole or placebo, followed by 40 weeks of open-label ropinirole treatment.. Patients had no previous history of augmentation. Potential cases of augmentation were identified with the Structured Interview for the Diagnosis of Augmentation and the Augmentation Severity Rating Scale and through reporting of adverse events. Cases were blindly evaluated by an expert panel using the NIH diagnostic criteria for augmentation. Four hundred and four patients participated in the double-blind study and 269 in the open-label phase, with a discontinuation rate of 42%. IRLS baseline scores improved at the end of the double-blind (DB) phase (mean ± SE) by -15.9 ± 0.76 for ropinirole, by -13.4 ± 0.77 for placebo (P < .05) and by -20.4 ± 0.55 during the open-label phase. The incidence rates of augmentation were 3.5% for ropinirole and <1% for placebo during the DB phase and 3% during the open-label phase. Clinically significant augmentation occurred in 3%, <1%, and 2%, respectively. Discontinuation of treatment occurred in 50% of all patients (7 of 14) with augmentation. The incidence of augmentation was 3.1 % higher with ropinirole than with placebo. New patients with first episodes of augmentation continued to cumulate at a stable rate over the duration of this study.
Affiliations:
- Autriche, Espagne, Italie, États-Unis
- Caroline du Nord, Communauté de Madrid, Lombardie, Maryland, Massachusetts
- Madrid, Milan
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:12-0113805Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Systematic Evaluation of Augmentation during Treatment with Ropinirole in Restless Legs Syndrome (Willis-Ekbom Disease): Results from a Prospective, Multicenter Study over 66 Weeks</title>
<author><name sortKey="Garcia Borreguero, Diego" sort="Garcia Borreguero, Diego" uniqKey="Garcia Borreguero D" first="Diego" last="Garcia-Borreguero">Diego Garcia-Borreguero</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Sleep Research Institute</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hogl, Birgit" sort="Hogl, Birgit" uniqKey="Hogl B" first="Birgit" last="Högl">Birgit Högl</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Innsbruck Medical University</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ferini Strambi, Luigi" sort="Ferini Strambi, Luigi" uniqKey="Ferini Strambi L" first="Luigi" last="Ferini-Strambi">Luigi Ferini-Strambi</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Università Vita-Salute San Raffaele, Sleep Disorders Center</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<placeName><settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Winkelman, John" sort="Winkelman, John" uniqKey="Winkelman J" first="John" last="Winkelman">John Winkelman</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Division of Sleep Medicine, Brigham & Women's Hospital, Harvard Medical School</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hill Zabala, Christina" sort="Hill Zabala, Christina" uniqKey="Hill Zabala C" first="Christina" last="Hill-Zabala">Christina Hill-Zabala</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>GlaxoSmithKline Research and Development, Research Triangle Park</s1>
<s2>North Carolina</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Asgharian, Afsaneh" sort="Asgharian, Afsaneh" uniqKey="Asgharian A" first="Afsaneh" last="Asgharian">Afsaneh Asgharian</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>GlaxoSmithKline Research and Development, Research Triangle Park</s1>
<s2>North Carolina</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Allen, Richard" sort="Allen, Richard" uniqKey="Allen R" first="Richard" last="Allen">Richard Allen</name>
<affiliation wicri:level="2"><inist:fA14 i1="06"><s1>Department of Neurology, Johns Hopkins University</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0113805</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0113805 INIST</idno>
<idno type="RBID">Pascal:12-0113805</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000282</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002A32</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000040</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Systematic Evaluation of Augmentation during Treatment with Ropinirole in Restless Legs Syndrome (Willis-Ekbom Disease): Results from a Prospective, Multicenter Study over 66 Weeks</title>
<author><name sortKey="Garcia Borreguero, Diego" sort="Garcia Borreguero, Diego" uniqKey="Garcia Borreguero D" first="Diego" last="Garcia-Borreguero">Diego Garcia-Borreguero</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Sleep Research Institute</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hogl, Birgit" sort="Hogl, Birgit" uniqKey="Hogl B" first="Birgit" last="Högl">Birgit Högl</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Innsbruck Medical University</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ferini Strambi, Luigi" sort="Ferini Strambi, Luigi" uniqKey="Ferini Strambi L" first="Luigi" last="Ferini-Strambi">Luigi Ferini-Strambi</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Università Vita-Salute San Raffaele, Sleep Disorders Center</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<placeName><settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Winkelman, John" sort="Winkelman, John" uniqKey="Winkelman J" first="John" last="Winkelman">John Winkelman</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Division of Sleep Medicine, Brigham & Women's Hospital, Harvard Medical School</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hill Zabala, Christina" sort="Hill Zabala, Christina" uniqKey="Hill Zabala C" first="Christina" last="Hill-Zabala">Christina Hill-Zabala</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>GlaxoSmithKline Research and Development, Research Triangle Park</s1>
<s2>North Carolina</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Asgharian, Afsaneh" sort="Asgharian, Afsaneh" uniqKey="Asgharian A" first="Afsaneh" last="Asgharian">Afsaneh Asgharian</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>GlaxoSmithKline Research and Development, Research Triangle Park</s1>
<s2>North Carolina</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Allen, Richard" sort="Allen, Richard" uniqKey="Allen R" first="Richard" last="Allen">Richard Allen</name>
<affiliation wicri:level="2"><inist:fA14 i1="06"><s1>Department of Neurology, Johns Hopkins University</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Evaluation</term>
<term>Multicenter study</term>
<term>Nervous system diseases</term>
<term>Prospective</term>
<term>Restless legs syndrome</term>
<term>Ropinirole</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Syndrome des jambes sans repos</term>
<term>Pathologie du système nerveux</term>
<term>Evaluation</term>
<term>Traitement</term>
<term>Ropinirole</term>
<term>Prospective</term>
<term>Etude multicentrique</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Prospective</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The purpose of this study was to evaluate the incidence of augmentation over 66 weeks of treatment with ropinirole in patients with primary restless legs syndrome (RLS). Augmentation is the main complication of long-term dopaminergic treatment of RLS. Despite widespread use of ropinirole in RLS, no studies have prospectively and systematically assessed the incidence of augmentation with its use. The study consisted of 26 weeks of double-blind flexible-dose treatment with ropinirole or placebo, followed by 40 weeks of open-label ropinirole treatment.. Patients had no previous history of augmentation. Potential cases of augmentation were identified with the Structured Interview for the Diagnosis of Augmentation and the Augmentation Severity Rating Scale and through reporting of adverse events. Cases were blindly evaluated by an expert panel using the NIH diagnostic criteria for augmentation. Four hundred and four patients participated in the double-blind study and 269 in the open-label phase, with a discontinuation rate of 42%. IRLS baseline scores improved at the end of the double-blind (DB) phase (mean ± SE) by -15.9 ± 0.76 for ropinirole, by -13.4 ± 0.77 for placebo (P < .05) and by -20.4 ± 0.55 during the open-label phase. The incidence rates of augmentation were 3.5% for ropinirole and <1% for placebo during the DB phase and 3% during the open-label phase. Clinically significant augmentation occurred in 3%, <1%, and 2%, respectively. Discontinuation of treatment occurred in 50% of all patients (7 of 14) with augmentation. The incidence of augmentation was 3.1 % higher with ropinirole than with placebo. New patients with first episodes of augmentation continued to cumulate at a stable rate over the duration of this study.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>27</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Systematic Evaluation of Augmentation during Treatment with Ropinirole in Restless Legs Syndrome (Willis-Ekbom Disease): Results from a Prospective, Multicenter Study over 66 Weeks</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>GARCIA-BORREGUERO (Diego)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>HÖGL (Birgit)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>FERINI-STRAMBI (Luigi)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>WINKELMAN (John)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>HILL-ZABALA (Christina)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>ASGHARIAN (Afsaneh)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>ALLEN (Richard)</s1>
</fA11>
<fA14 i1="01"><s1>Sleep Research Institute</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurology, Innsbruck Medical University</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Università Vita-Salute San Raffaele, Sleep Disorders Center</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Division of Sleep Medicine, Brigham & Women's Hospital, Harvard Medical School</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>GlaxoSmithKline Research and Development, Research Triangle Park</s1>
<s2>North Carolina</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Neurology, Johns Hopkins University</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>277-283</s1>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000508698420170</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>21 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0113805</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The purpose of this study was to evaluate the incidence of augmentation over 66 weeks of treatment with ropinirole in patients with primary restless legs syndrome (RLS). Augmentation is the main complication of long-term dopaminergic treatment of RLS. Despite widespread use of ropinirole in RLS, no studies have prospectively and systematically assessed the incidence of augmentation with its use. The study consisted of 26 weeks of double-blind flexible-dose treatment with ropinirole or placebo, followed by 40 weeks of open-label ropinirole treatment.. Patients had no previous history of augmentation. Potential cases of augmentation were identified with the Structured Interview for the Diagnosis of Augmentation and the Augmentation Severity Rating Scale and through reporting of adverse events. Cases were blindly evaluated by an expert panel using the NIH diagnostic criteria for augmentation. Four hundred and four patients participated in the double-blind study and 269 in the open-label phase, with a discontinuation rate of 42%. IRLS baseline scores improved at the end of the double-blind (DB) phase (mean ± SE) by -15.9 ± 0.76 for ropinirole, by -13.4 ± 0.77 for placebo (P < .05) and by -20.4 ± 0.55 during the open-label phase. The incidence rates of augmentation were 3.5% for ropinirole and <1% for placebo during the DB phase and 3% during the open-label phase. Clinically significant augmentation occurred in 3%, <1%, and 2%, respectively. Discontinuation of treatment occurred in 50% of all patients (7 of 14) with augmentation. The incidence of augmentation was 3.1 % higher with ropinirole than with placebo. New patients with first episodes of augmentation continued to cumulate at a stable rate over the duration of this study.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Syndrome des jambes sans repos</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Restless legs syndrome</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Acroparestesia nocturna</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Evaluation</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Evaluation</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Evaluación</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Traitement</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Treatment</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Ropinirole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Ropinirole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Ropinirol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Prospective</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Prospective</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Prospectiva</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Etude multicentrique</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Multicenter study</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Estudio multicéntrico</s0>
<s5>13</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>38</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>38</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Trouble de la sensibilité</s0>
<s5>39</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Sensitivity disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Trastorno sensibilidad</s0>
<s5>39</s5>
</fC07>
<fN21><s1>086</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
<affiliations><list><country><li>Autriche</li>
<li>Espagne</li>
<li>Italie</li>
<li>États-Unis</li>
</country>
<region><li>Caroline du Nord</li>
<li>Communauté de Madrid</li>
<li>Lombardie</li>
<li>Maryland</li>
<li>Massachusetts</li>
</region>
<settlement><li>Madrid</li>
<li>Milan</li>
</settlement>
</list>
<tree><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Garcia Borreguero, Diego" sort="Garcia Borreguero, Diego" uniqKey="Garcia Borreguero D" first="Diego" last="Garcia-Borreguero">Diego Garcia-Borreguero</name>
</region>
</country>
<country name="Autriche"><noRegion><name sortKey="Hogl, Birgit" sort="Hogl, Birgit" uniqKey="Hogl B" first="Birgit" last="Högl">Birgit Högl</name>
</noRegion>
</country>
<country name="Italie"><region name="Lombardie"><name sortKey="Ferini Strambi, Luigi" sort="Ferini Strambi, Luigi" uniqKey="Ferini Strambi L" first="Luigi" last="Ferini-Strambi">Luigi Ferini-Strambi</name>
</region>
</country>
<country name="États-Unis"><region name="Massachusetts"><name sortKey="Winkelman, John" sort="Winkelman, John" uniqKey="Winkelman J" first="John" last="Winkelman">John Winkelman</name>
</region>
<name sortKey="Allen, Richard" sort="Allen, Richard" uniqKey="Allen R" first="Richard" last="Allen">Richard Allen</name>
<name sortKey="Asgharian, Afsaneh" sort="Asgharian, Afsaneh" uniqKey="Asgharian A" first="Afsaneh" last="Asgharian">Afsaneh Asgharian</name>
<name sortKey="Hill Zabala, Christina" sort="Hill Zabala, Christina" uniqKey="Hill Zabala C" first="Christina" last="Hill-Zabala">Christina Hill-Zabala</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000040 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000040 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PascalFrancis |étape= Checkpoint |type= RBID |clé= Pascal:12-0113805 |texte= Systematic Evaluation of Augmentation during Treatment with Ropinirole in Restless Legs Syndrome (Willis-Ekbom Disease): Results from a Prospective, Multicenter Study over 66 Weeks }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |